By Ben Glickman
Kronos Bio said it would cut about 83% of its workforce by the end of the year and named a new interim chief executive, as the company continues to explore strategic options.
The San Mateo, Calif., biotechnology company said Wednesday that Deborah Knobelman had been appointed president and interim CEO, effective Dec. 3.
CEO Norbert Bischofberger, who has been with the company since 2018, will step down while remaining on the board of directors.
Kronos said the workforce reduction was part of its previously announced plan to cut costs and is expected to be completed by the end of the year. The company is exploring options, including a possible business combination or divestiture of its assets.
The cuts follow a 21% workforce reduction which was announced in March. Kronos expects to incur a charge of about $3.7 million related to the reduction.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
November 27, 2024 07:47 ET (12:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.